Michael Wagner
Prof. Dr. Michael Wagner
  • Klinik für Neurodegenerative Erkrankungen und Gerontopsychatrie, Universitätsklinikum Bonn
  • Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)
  • Alzheimer's disease
  • preclinical Alzheimer's disease
With a background in clinical and experimental neuropsychology, I am interested in the detection of neurocognitive and brain changes in Alzheimer’s Disease, (AD) which has a preclinical duration of many years before progressive neuronal changes give rise to clear-cut cognitive impairments. We have contributed to establishing Subjective Cognitve Decline as a stage of preclinical AD. Working with psychometric and brain imaging methods, we examine risk and protective factors for AD, including genetic factors, cognitive reserve and lifestyle, including dietary habits and nutrition. Finally, we are involved in clinical interventional trials with sensitive and targeted outcomes, in order to establish treatments for early AD.
Ausgewählte Publikationen

Ballarini T, van Lent DM, Brunner J, ..., Wagner M (2021) Mediterranean Diet, Alzheimer Disease Biomarkers and Brain Atrophy in Old Age. Neurology 96(24):e2920-32.

Jessen F, Amariglio RE, Buckley RF, ..., Wagner M (2021). The characterisation of subjective cognitive decline. Lancet Neurol 19: 271–278.

Wolfsgruber S, Kleineidam L, Guski J, ..., Wagner M (2020) Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology 95(9):e1134-e1143.

Miebach L, Wolfsgruber S, Polcher A, ..., Wagner M (2019) Which features of subjective cognitive decline are related to amyloid pathology? Alzheimers Res Ther 11: 66.

Michael Wagner
Prof. Dr. Michael Wagner
Wird geladen